현재 위치
Home
SYM-1, Session I: Glycobiology I, Chair: Hynu Ah Kang (Chungang University)
Achievements and vision of the global network for cancer biomarker development
-
- 발행기관
- 한국당과학회 바로가기
-
- 간행물
- 한국당과학회 학술대회 바로가기
-
- 통권
- 2011 한국당과학회 동계 학술대회 (2011.01)바로가기
-
- 페이지
- pp.2-2
-
- 저자
-
- 언어
- 영어(ENG)
-
- URL
- https://www.earticle.net/Article/A192606
※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.
원문정보
초록
- 영어
- Our center, Daejeon-KRIBB-FHCRC Research Cooperation Center, was established to develop ‘cancer biomarkers’ in collaboration with Fred Hutchinson Cancer Research Center (FHCRC) in Feb. 2005 with supports from the Daejeon Metropolitan City. Cancer is often difficult to achieve early diagnosis, which is, however, a decisive requisite for favorable outcome in cancer treatments. In order to develop the cancer biomarkers, we’ve tried to pinpoint cancer cells-originating aberrant glycoproteins which would be a well-grounded approach to cancer biomarker discovery ultimately using blood. One of the glycosyltransferases responsible for aberrant glycosylation in cancer is N-acetylglucosaminyltransferase V (GnT-V), which catalyzes an addition of b1,6-N-acetylglucosamine (GlcNAc) to the core N-glycan, and many lines of evidence have demonstrated the role of N-acetylglucosaminyltransferase V (GnT-V) in cancer development. Tissue inhibitor of metalloproteinase-1 (TIMP-1) and protein tyrosine phosphatase kappa (PTPk) were good models involved in cancer malignancy upon aberrantly glycosylation. Basically by adopting multi-lectins enrichment strategy, candidate proteins showing high sensitivity and specificity during the discovery phase were selected and the panel of biomarker candidates is currently under in-depth analyses for validation. Validation is a time-consuming step for biomarker developments requiring confirmation of the biomarker candidates through multiple pairs of clinical samples. That is why a sensitive, multiplexing validation method is necessary. To address this challenge, we are developing as a DNA-tagged antibody-based ‘New’ validation method, enabling a multiplexed validation of biomarkers. Furthermore, the collaboration with the FHCRC leads to an expansion of the ‘epigenetic’ studies to ‘glycogenome’, requiring incessant collaborations. Recently, Daejeon Metropolitan City became a ‘sister city’ for Sapporo City in Japan. It’s noteworthy that these relationships prompt to establish a ‘north pacific network of cancer biomarker development’ among the KRIBB, FHCRC and Sapporo Medical University.
저자
간행물 정보
발행기관
-
- 발행기관명
- 한국당과학회 [Korean Society for Glycoscience]
- 설립연도
- 2006
- 분야
- 의약학>약학
- 소개
- 본 학회는 화학, 생화학, 분자생물학, 미생물학, 식품공학, 의학, 약학, 유전공학 및 생물공학, 환경 및 기타 공업 등 전 분야의 탄수화물관련 이론과 기술을 연구 발전시키고 산학협동을 통해 이를 보급하여 국내 관련 산업의 발전 및 국민생활의 과학화에 기여하고자 하며, 이러한 목표와 비젼의 실현을 위해 회원들이 적극적인 참여와 활동을 전개하고자 한다.
간행물
-
- 간행물명
- 한국당과학회 학술대회
- 간기
- 연간
- 수록기간
- 2006~2022
- 십진분류
- KDC 517 DDC 614
이 권호 내 다른 논문 / 한국당과학회 학술대회 2011 한국당과학회 동계 학술대회
피인용수 : 0건 (자료제공 : 네이버학술정보)
함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.
출처 : 네이버학술정보
0개의 논문이 장바구니에 담겼습니다.